Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Scientific ReportsOpen Access

Evaluating the efficacy of neoadjuvant immunotherapy combined with chemotherapy for stage IIIa non-small cell lung cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

RSRuiqiang SongZCZhixiang ChenHainan UniversityTZTianxi Zheng

Discussion

Loading...

Member takes

Implication

Retrospective analysis reveals improved survival and resection rates in stage IIIa NSCLC with neoadjuvant immunotherapy and chemotherapy.

Key Points

  • The experimental group had significantly higher objective response rates and superior R0 resection rates.
  • Overall survival and progression-free survival were longer for patients receiving neoadjuvant immunotherapy and chemotherapy.
  • Postoperative complications were significantly reduced in the experimental group compared to the control group.
  • Safety assessments indicated no significant differences in routine blood counts between treatment groups.

Cite This Study

Song et al. (2025) studied this question.

synapsesocial.com/papers/68c23ed7b210217d647937d3https://doi.org/10.1038/s41598-025-13917-0
View Full Paper
Ask AI
Bookmark
Share